UnitedHealthcare Chemotherapy Inpatient Coverage Update

Coverage Criteria — Observation vs Inpatient

Regimens warranting inpatient stay

Inpatient stay is medically necessary for drug regimens that require inpatient monitoring or complex administration over multiple days, including when the listed factors contributing to the need for inpatient stay are present.

EPOCH/DA-EPOCH/R-EPOCH: EPOCH, DA-EPOCH, or R-EPOCH: Etoposide 50 mg/m2/day continuous infusion days 1–4; prednisone; vincristine IV days 1–4; cyclophosphamide 750 mg/m2 IV on day 5; doxorubicin 10 mg/m2/day continuous infusion days 1–4; with or without rituximab.

Factors: coordination of multiple infusions or multiple drugs over 96 hours.

ESHAP/R-ESHAP: ESHAP or R-ESHAP: Etoposide 40 mg/m2/day continuous infusion days 1–4; methylprednisolone; cytarabine 2 g/m2 (high‑dose); cisplatin 25 mg/m2 continuous infusion days 1–4; with or without rituximab.

Factors: coordination of multiple infusions or multiple drugs over 96 hours; monitor for CNS toxicity with cytarabine.

Interleukin-2 infusion: Interleukin‑2 infusion: Interleukin‑2 600,000 IU/kg IV every 8 hours for up to 14 consecutive doses over 5 days.

Factors: continuous cardiac monitoring; close monitoring of serum electrolytes, creatinine, bilirubin, and urine output; potential vasopressor support; proximity to ICU.

High‑dose ifosfamide: Ifosfamide infusion > 1 g/m2/day.

Factors: close monitoring of serum electrolytes and urine pH; replacement of electrolytes; alkalinization of urine.

High‑dose methotrexate with leucovorin rescue: Methotrexate dose > 500 mg/m2 with leucovorin rescue (leucovorin 15 mg every 6 hours for eight doses beginning 12 hours after completion of methotrexate infusion; increase to 50 mg IV every 6 hours if methotrexate levels exceed specified thresholds) until levels are < 0.1 µmol/L.

Factors: close monitoring of serum methotrexate levels and adjustment of leucovorin dosing per measured levels.

Hyper‑CVAD: Cycles 1,3,5,7 and cycles 2,4,6,8 schema including cyclophosphamide, mesna, vincristine, doxorubicin, dexamethasone, and high‑dose methotrexate/cytarabine portions (see dosing details in policy).

Factors: coordination of multiple infusions over 96 hours; bladder irrigation with cyclophosphamide; close monitoring of serum methotrexate levels.

Observation indications

Observation stay may be required for the following clinical conditions or complications:

Observation indications: Congestive heart failure or chronic renal failure requiring high‑volume fluid infusions.

May require observation rather than inpatient admission depending on severity.

Observation indications: Known hypersensitivity reactions from a previous infusion.

May require observation rather than inpatient admission depending on severity.

Observation indications: TACE (Transcatheter Arterial Chemoembolization) or intra‑arterial chemotherapy infusion.

May require observation rather than inpatient admission depending on severity.

This policy does not apply to individuals under 18 years of age. The coverage criteria and recommendations described here are intended for adult members only and should not be used to determine care or authorization for pediatric patients.

Information about U.S. Food and Drug Administration (FDA) approvals is provided for context only. FDA approval alone is not a basis for coverage; coverage decisions are made by comparing the drug or regimen’s clinical use to the benefit plan’s medical necessity criteria and applicable contractual, state, or federal requirements.

Regimen	Drugs / Dosing (as stated in policy)	Factors contributing to need for inpatient stay	Coverage stance
EPOCH / DA‑EPOCH / R‑EPOCH	Etoposide 50 mg/m2/day continuous infusion days 1–4; prednisone; vincristine IV days 1–4; cyclophosphamide 750 mg/m2 IV on day 5; doxorubicin 10 mg/m2/day continuous infusion days 1–4; with or without rituximab	Coordination of multiple infusions or multiple drugs over 96 hours	Covered with criteria
ESHAP / R‑ESHAP	Etoposide 40 mg/m2/day continuous infusion days 1–4; methylprednisolone; cytarabine (high‑dose Ara‑C) 2 g/m2; cisplatin 25 mg/m2 continuous infusion days 1–4; with or without rituximab	Coordination of multiple infusions or multiple drugs over 96 hours; monitor for CNS toxicity with cytarabine	Covered with criteria
Interleukin‑2 infusion	Interleukin‑2 600,000 IU/kg IV every 8 hours for up to 14 consecutive doses over 5 days	Continuous cardiac monitoring; close monitoring of electrolytes/creatinine/bilirubin/urine output; vasopressor support; proximity to ICU	Covered with criteria
High‑dose ifosfamide	Ifosfamide infusion > 1 g/m2/day	Close monitoring of serum electrolytes and urine pH; replacement of electrolytes; alkalinization of urine	Covered with criteria
High‑dose methotrexate with leucovorin rescue	Methotrexate dose > 500 mg/m2; leucovorin 15 mg every 6 hours for eight doses beginning 12 hours after completion of methotrexate infusion, increased to 50 mg IV every 6 hours per methotrexate level thresholds until levels < 0.1 µmol/L	Close monitoring of serum methotrexate levels	Covered with criteria
Hyper‑CVAD	Cycles 1,3,5,7: cyclophosphamide 300 mg/m2 IV over 2 hours every 12 hours for six doses; mesna 600 mg/m2/day continuous infusion days 1–3; vincristine; doxorubicin 50 mg/m2 IV on day 4; dexamethasone. Cycles 2,4,6,8: methotrexate 200 mg/m2 IV over 2 hours followed by 800 mg/m2 IV over 22 hours on day 1 plus cytarabine 3 g/m2 (1 g/m2 for individuals >60 years) IV over 2 hours every 12 hours for four doses starting on day 2; leucovorin per methotrexate rescue dosing; methylprednisolone 50 mg	Coordination of multiple infusions or multiple drugs over 96 hours; bladder irrigation with cyclophosphamide; close monitoring of serum methotrexate levels	Covered with criteria

Regimen / Topic	Notes from policy and references	Outpatient feasibility / discussion	Coverage stance
Dose‑adjusted EPOCH (DA‑EPOCH) as outpatient	Policy lists DA‑EPOCH among regimens that may require inpatient monitoring when factors are present; referenced literature reports outpatient DA‑EPOCH as safe and tolerated in selected settings (see Nelles et al. 2023; Keshvani et al. 2019).	Outpatient administration may be feasible in selected patients and centers with appropriate monitoring and protocols; decisions should consider coordination of multiple infusions over 96 hours and patient risk factors	Informational
High‑dose cytarabine (Ara‑C)	Policy references high‑dose cytarabine in Hyper‑CVAD and notes need for CNS toxicity monitoring with cytarabine; literature includes outpatient high‑dose cytarabine feasibility reports (Rodrigues et al. 2020).	Outpatient high‑dose cytarabine has been reported as feasible in selected populations with monitoring protocols; consider patient comorbidities and toxicity risk	Informational
High‑dose ifosfamide (outpatient discussion)	Policy defines high‑dose ifosfamide as infusion >1 g/m2/day and indicates need for close electrolyte and urine pH monitoring; recent literature describes prolonged outpatient infusional ifosfamide in select cohorts (Tirtei et al. 2024; Banh et al. 2022).	Some centers have transitioned ifosfamide regimens to ambulatory settings with protocols for safety monitoring, but inpatient stay may be required for electrolyte/urine pH management or other risk factors	Informational
TACE (Transcatheter Arterial Chemoembolization)	Policy lists TACE/intra‑arterial chemotherapy as situations that may require an observation stay; NCI definition cited.	TACE often requires facility‑level monitoring post‑procedure; observation vs inpatient admission depends on severity and institutional practice	Informational
Other referenced regimens	Policy and references note additional regimens and studies addressing outpatient transition, safety, and financial considerations for selected infusional therapies (see References).	Outpatient feasibility depends on regimen complexity, monitoring needs, local protocols, and patient comorbidities; case‑by‑case review recommended	Informational

Provider Responsibilities and Prior Authorization Guidance

Prior Authorization

Extensions Require Clinical Review

Any requests for an extension of an inpatient stay beyond the recommended day(s) must be submitted for clinical review and justification. Extensions will be evaluated on a case-by-case basis using clinical criteria and may require additional documentation to support medical necessity.

Extensions to inpatient stays require clinical review and justification.
Case-by-case review may reference InterQual criteria for individualized determination.

Documentation Required

Provider Obligations and Review Tools

Providers are expected to follow a written protocol when administering chemotherapy drugs. UnitedHealthcare may use tools developed by third parties (for example, InterQual® criteria) to assist in administering health benefits. Coverage determinations are governed by applicable federal, state, or contractual benefit plan requirements; in the event of a conflict, those requirements control. This policy is informational and does not replace plan-specific prior authorization or other benefit rules.

Regimens Requiring Inpatient Monitoring

Example multi‑day / high‑risk regimen	Key dosing details (policy text)	Monitoring / inpatient requirements	Coverage stance
EPOCH / DA‑EPOCH / R‑EPOCH	Etoposide 50 mg/m2/day continuous infusion days 1–4; prednisone; vincristine IV days 1–4; cyclophosphamide 750 mg/m2 IV on day 5; doxorubicin 10 mg/m2/day continuous infusion days 1–4; with or without rituximab	Requires coordination of multiple infusions/drugs over 96 hours — may necessitate inpatient monitoring	Covered with criteria
ESHAP / R‑ESHAP	Etoposide 40 mg/m2/day continuous infusion days 1–4; methylprednisolone; cytarabine 2 g/m2; cisplatin 25 mg/m2 continuous infusion days 1–4; with or without rituximab	Coordination of multiple infusions/drugs over 96 hours; monitor for CNS toxicity with cytarabine	Covered with criteria
Hyper‑CVAD (including high‑dose methotrexate/cytarabine phase)	Cycles 1,3,5,7: cyclophosphamide 300 mg/m2 IV every 12 hours for six doses; mesna 600 mg/m2/day continuous infusion days 1–3; vincristine; doxorubicin 50 mg/m2 IV on day 4; dexamethasone. Cycles 2,4,6,8: methotrexate 200 mg/m2 IV over 2 hours followed by 800 mg/m2 IV over 22 hours on day 1 plus cytarabine 3 g/m2 (1 g/m2 for individuals >60 years) IV over 2 hours every 12 hours for four doses starting on day 2; leucovorin rescue per policy	Coordination of multiple infusions over 96 hours; bladder irrigation for cyclophosphamide; close monitoring of serum methotrexate levels	Covered with criteria
High‑dose methotrexate with leucovorin rescue	Methotrexate > 500 mg/m2; leucovorin 15 mg every 6 hours for eight doses beginning 12 hours after methotrexate infusion, escalate to 50 mg IV every 6 hours if methotrexate levels exceed thresholds	Close monitoring of serum methotrexate levels; inpatient monitoring may be required for level‑guided rescue	Covered with criteria
High‑dose ifosfamide	Ifosfamide infusion > 1 g/m2/day	Close monitoring of electrolytes and urine pH; replacement of electrolytes; urine alkalinization — may require inpatient care	Covered with criteria
Interleukin‑2 infusion	Interleukin‑2 600,000 IU/kg IV every 8 hours for up to 14 consecutive doses over 5 days	Continuous cardiac monitoring; intensive electrolyte/renal/hepatic/urine output monitoring; potential vasopressor support; proximity to ICU required	Covered with criteria

Regimen / Topic	Policy note and reference	Outpatient feasibility considerations	Coverage stance
Dose‑adjusted EPOCH (DA‑EPOCH)	Policy includes DA‑EPOCH among regimens that may require inpatient monitoring when contributing factors are present; literature reports outpatient DA‑EPOCH is safe and tolerated in selected patients (Nelles et al. 2023; Keshvani et al. 2019).	Feasible outpatient in experienced centers with protocols, patient selection, and monitoring; consider coordination of infusions over 96 hours and local resources	Informational
High‑dose cytarabine	Referenced in Hyper‑CVAD and elsewhere; policy notes need to monitor for CNS toxicity with cytarabine; studies report outpatient high‑dose cytarabine feasibility in select cohorts (Rodrigues et al. 2020).	Outpatient administration may be possible with strict monitoring protocols and appropriate patient selection; risk of CNS toxicity and other complications may necessitate inpatient care	Informational
High‑dose ifosfamide	Policy defines high‑dose ifosfamide as >1 g/m2/day and notes monitoring needs; recent literature describes prolonged outpatient infusional ifosfamide in selected patients (Tirtei et al. 2024; Banh et al. 2022).	Ambulatory infusion has been implemented in some centers with safety protocols, but electrolyte/urine pH management or other complications may require inpatient monitoring	Informational
TACE / intra‑arterial chemotherapy	Policy lists TACE as an indication that may require observation stay; NCI definition cited in references.	TACE frequently requires post‑procedure facility monitoring; observation vs inpatient admission depends on severity and institutional practice	Informational

Definitions and Regulatory Notes

TACE definition

TermTACE (Transcatheter Arterial Chemoembolization)

DefinitionA procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (National Cancer Institute, 2022).

SourceNational Cancer Institute, 2022 (as cited in policy).

FDA approval definition/note

TopicU.S. Food and Drug Administration (FDA)

Key pointFDA approval occurs once data are reviewed by the Center for Drug Evaluation and Research and it is determined benefits outweigh risks in the intended population.

Clinical Background

Chemotherapy may be administered in multiple settings including home, physician office, outpatient clinic, or hospital. The appropriate setting is determined by the specific drug regimen, the route and complexity of administration, and the patient’s clinical condition and comorbidities.

An inpatient stay is considered medically necessary when a regimen requires facility monitoring or complex multi-day administration—for example, protocols that coordinate multiple continuous infusions or multiple drugs over a 96-hour period, or when close physiologic monitoring (electrolytes, renal/hepatic function, urine output, hemodynamic support) is required due to known toxicity risks.

Policy Revision History

06/01/2026material changeLatest

Revised drug regimen requirements for an inpatient stay and removed the list of applicable cancer types for the listed regimens; updated Clinical Evidence and References and archived prior policy CS305IN.08.

OpenPayer

Chemotherapy Observation or Inpatient Hospitalization (for Indiana Only)

Coverage Criteria — Observation vs Inpatient

Provider Responsibilities and Prior Authorization Guidance

Regimens Requiring Inpatient Monitoring

Definitions and Regulatory Notes

Clinical Background

Policy Revision History